Corrigendum to 'Subcutaneous versus intravenous nivolumab for renal cell carcinoma': [Annals of Oncology volume 36 (2025) 99-107] [0.03%]
有关《肾细胞癌的皮下给药与静脉给药尼伏鲁马比照：》的更正([牛津肿瘤年鉴>第36卷（2025）99-107])
L Albiges,M T Bourlon,M Chacón et al.
L Albiges et al.
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study [0.03%]
一种无化疗、基于病理反应适应性使用的曲妥珠单抗-帕妥珠单抗和T-DM1在HER2阳性早期乳腺癌中的策略：PHERGain-2研究
L Garrigós,M Ruiz-Borrego,J M Pérez-García et al.
L Garrigós et al.
Background: PHERGain-2 is a multicenter, single-arm, phase II study evaluating a pathologic complete response (pCR)-guided de-escalation strategy to omit chemotherapy in selected patients with HER2-positive early breast c...
Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer [0.03%]
利法林马布联合卡铂-紫杉醇一线治疗局部晚期不可切除或转移性肛管鳞癌患者的POD1UM-303/InterAACT-2期临床研究：生存结局
S Rao,E Samalin-Scalzi,L Evesque et al.
S Rao et al.
Background: In the primary analysis of the POD1UM-303/InterAACT 2 trial, median progression-free survival (PFS) was significantly longer with retifanlimab plus carboplatin-paclitaxel than with placebo plus carboplatin-pac...
Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls [0.03%]
针对调节性T细胞的肿瘤免疫治疗：前景与挑战
O Mirallas,G Pretelli,M Balsa et al.
O Mirallas et al.
Background: Regulatory T cells (Tregs) form a distinct subset of CD4+ T cells essential for maintaining immune balance and preventing autoimmunity by expressing CD25 and CTLA-4. Tregs, which are defined by the expression ...
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers? [0.03%]
肺癌脑转移治疗步入精准医学时代：准备好了打破局限吗？
A Mavrikios,M Bortolot,C Le Péchoux et al.
A Mavrikios et al.
Brain metastases (BM) occur in nearly half of patients with lung cancer and significantly impair survival and quality of life. Historically, limited blood-brain barrier penetration and low intracranial efficacy of systemic therapies restric...
Beyond single-target ADCs: are bispecific conjugates the next step in EGFR-mutated NSCLC? [0.03%]
单一靶点ADC之后：EGFR突变型NSCLC的双特异性偶联药物会是下一步吗？
M Y Jeng,G J Riely
M Y Jeng
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival [0.03%]
将肿瘤浸润性淋巴细胞纳入PREDICT模型以预测三阴性乳腺癌患者的生存预后
Y Wang,D Drubay,S F Jonas et al.
Y Wang et al.
Background: Stromal tumor infiltrating lymphocytes (sTILs) are a strong prognostic marker in triple-negative breast cancer (TNBC) patients. We aimed to incorporate sTILs into the PREDICT model for women with early-stage T...
Colorectal cancer detection using non-contrast CT and deep learning: a multicenter and international cohort study [0.03%]
基于非对比剂CT和深度学习的结直肠癌检测的多中心国际队列研究
X Chen,M Y Qiu,J P Zhang et al.
X Chen et al.
Background: Colorectal cancer (CRC) is a leading cause of cancer deaths, with early screening vital to reduce mortality. While methods like colonoscopy and CT colonography are available, they face challenges such as bowel...
Re-Evaluating Antibody-Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation [0.03%]
重新评估抗体药物偶联物连接子的稳定性：评估、解读和临床转化
R Colombo,S Seredick,S D Barnscher et al.
R Colombo et al.
Antibody-drug conjugates (ADCs) have emerged as an important class of anticancer therapeutics. Their highly modular design offers multiple opportunities to refine their properties and improve clinical performance by tuning individual compon...
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma [0.03%]
特瑞普利单抗联合IO102或IO103治疗既往接受过多种系统抗肿瘤治疗的晚期恶性黑色素瘤患者的多中心、开放性、Ib期临床研究
J C Hassel,A Arance,M S Carlino et al.
J C Hassel et al.
Background: IO102-IO103, an investigational, immune-modulatory cancer vaccine, targets both tumor cells and immune-suppressive cells within the tumor microenvironment through activation and expansion of T cells against in...